Cabozantinib

Last Updated: 06/30/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 2158 publications

A Single-Institution, Exploratory, Retrospective Observational Study on Nausea during Cabozantinib Administration with Antiemetic Therapy.

A Single-Institution, Exploratory, Retrospective Observational Study on Nausea during Cabozantinib Administration with Antiemetic Therapy.

Journal: Biological & pharmaceutical bulletin
Published: June 17, 2026

Clinical response with cabozantinib plus nivolumab, a first-line therapy in advanced renal cell carcinoma: a clinical case report.

Clinical response with cabozantinib plus nivolumab, a first-line therapy in advanced renal cell carcinoma: a clinical case report.

Journal: Clinical advances in hematology & oncology : H&O
Published: June 12, 2026

TKI-associated proteinuria and nephrotic syndrome: a narrative review with clinical illustration in radio-iodine-refractory thyroid cancer.

TKI-associated proteinuria and nephrotic syndrome: a narrative review with clinical illustration in radio-iodine-refractory thyroid cancer.

Journal: Acta clinica Belgica
Published: June 07, 2026

Targeted therapies in thoracic neuroendocrine tumors: challenges and failures of tyrosine kinase inhibition in lung and thymic carcinoids.

Targeted therapies in thoracic neuroendocrine tumors: challenges and failures of tyrosine kinase inhibition in lung and thymic carcinoids.

Journal: Expert opinion on pharmacotherapy
Published: June 07, 2026

Discovery of Casdatifan, Part II: A Potent and Orally Bioavailable Inhibitor of Hypoxia Inducible Factor-2α.

Discovery of Casdatifan, Part II: A Potent and Orally Bioavailable Inhibitor of Hypoxia Inducible Factor-2α.

Journal: Journal of medicinal chemistry
Published: June 05, 2026

Sex-Specific Adverse Events and Cardiovascular Toxicity of Cabozantinib in Renal Cell Carcinoma: A Nine-Year Pharmacovigilance Study.

Sex-Specific Adverse Events and Cardiovascular Toxicity of Cabozantinib in Renal Cell Carcinoma: A Nine-Year Pharmacovigilance Study.

Journal: Cancer investigation
Published: May 29, 2026

Cabozantinib plus nivolumab as first-line therapy for advanced renal cell carcinoma with bone metastases: a clinical case report.

Cabozantinib plus nivolumab as first-line therapy for advanced renal cell carcinoma with bone metastases: a clinical case report.

Journal: Clinical advances in hematology & oncology : H&O
Published: May 07, 2026

FDA-approved RET protein-tyrosine kinase inhibitors in the management of RET-driven thyroid and lung cancer.

FDA-approved RET protein-tyrosine kinase inhibitors in the management of RET-driven thyroid and lung cancer.

Journal: Pharmacological research
Published: May 05, 2026

Clinical Outcomes and Therapeutic Response in Adult TFE3-Related Renal Cell Carcinoma: A Case Series From a Tertiary Cancer Center in Southern India.

Clinical Outcomes and Therapeutic Response in Adult TFE3-Related Renal Cell Carcinoma: A Case Series From a Tertiary Cancer Center in Southern India.

Journal: Cureus
Published: April 25, 2026

Clinical and Molecular Validation of the Very Favorable IMDC Risk Group in Metastatic Renal Cell Carcinoma.

Clinical and Molecular Validation of the Very Favorable IMDC Risk Group in Metastatic Renal Cell Carcinoma.

Journal: JAMA network open
Published: April 15, 2026

A phase Ib/II single-arm study of cabozantinib plus dostarlimab in women with recurrent gynecologic carcinosarcoma.

A phase Ib/II single-arm study of cabozantinib plus dostarlimab in women with recurrent gynecologic carcinosarcoma.

Journal: Gynecologic oncology
Published: April 13, 2026

A systematic review on clinical pharmacokinetics and pharmacodynamics of antiangiogenic tyrosine kinase inhibitors (TKIs) with high TDM scores.

A systematic review on clinical pharmacokinetics and pharmacodynamics of antiangiogenic tyrosine kinase inhibitors (TKIs) with high TDM scores.

Journal: Expert review of anticancer therapy
Published: April 08, 2026
Showing 1-12 of 2,158

Last Updated: 06/30/2026